title: HIV-Nef enhances interleukin-2 production and phosphatidylinositol 3-kinase activity in a human T cell line.
abstract: OBJECTIVE
  The Nef protein has a major influence on disease pathogenesis in HIV-infected individuals. The objective of the present study was to examine the effects of Nef on T lymphocyte activation and associated signalling events.
  
  
  METHODS
  A recombinant vaccinia expression system was used to express Nef in a human T cell line. Stimulation of these cells with anti-CD28 antibody, and either phorbol 12-myristate 13-acetate (PMA) or anti-CD3, activates signal transduction pathways and results in IL-2 production and IL-2 receptor alpha-chain (CD25) expression. Cellular responses were examined in cells expressing either Nef or an irrelevant control protein.
  
  
  METHODS
  Activation of signalling was assessed by immunoblot analysis, or by in-vitro phosphatidylinositol 3-kinase (PI3K) assays. IL-2 production was measured by enzyme-linked immunosorbent assay, and CD25 cell surface expression was examined using flow cytometry.
  
  
  RESULTS
  Infection of cells with recombinant vaccinia expressing HIV-nef resulted in a marked increase in the production of IL-2 when cells were activated. The enhanced IL-2 response was accompanied by an increase in the level of PI3K activity. IL-2 production remained sensitive to inhibition with the PI3K competitive inhibitor Ly294002, and to the fungal macrolide, rapamycin. In contrast, CD25 expression was not affected, and there were no measurable changes to nuclear factor kappaB (NFkappaB) activation pathways.
  
  
  CONCLUSIONS
  Enhanced IL-2 production in stimulated T cells expressing HIV-Nef is associated with increased activation of PI3K-dependent signalling pathways. The results support a model in which Nef affects HIV disease progression by distorting T cell responses.
authors.affiliation: Department of Clinical Immunology, Westmead Hospital, NSW, Australia.
authors.forename: S D
authors.initials: SD
authors.lastname: Schibeci
authors.forename: A O
authors.initials: AO
authors.lastname: Clegg
authors.forename: R A
authors.initials: RA
authors.lastname: Biti
authors.forename: K
authors.initials: K
authors.lastname: Sagawa
authors.forename: G J
authors.initials: GJ
authors.lastname: Stewart
authors.forename: P
authors.initials: P
authors.lastname: Williamson
mesh_terms: D018106:CD28 Antigens; D004789:Enzyme Activation; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015967:Gene Expression Regulation, Viral; D015693:Gene Products, nef / Q000235:genetics / Q000502:physiology*; D015754:Genes, nef / Q000502:physiology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D015151:Immunoblotting; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000378:metabolism; D019169:Jurkat Cells; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis / Q000276:immunology; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000201:enzymology* / Q000276:immunology*; D054311:nef Gene Products, Human Immunodeficiency Virus
chemical_list: D018106:CD28 Antigens; D015693:Gene Products, nef; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D054311:nef Gene Products, Human Immunodeficiency Virus; D019869:Phosphatidylinositol 3-Kinases